Goldman Sachs analyst Matthew Sykes upgraded Twist Bioscience to Buy from Neutral with a price target of $45, up from $25. The analyst sees the company’s “critical new product launch” of Express Genes directly addressing Twist’s gross margin issues within its SynBio division. The firm believes Express Genes is a potential solution to the company’s gross margin issues and should allow Twist to “unlock” the gene maker market due to the significant improvement in turnaround time.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on TWST:
- Twist Bioscience appoints Adam Laponis as chief financial officer
- Twist Bioscience named a best idea for 2024 at TD Cowen
- Twist Bioscience price target raised to $30 from $26 at Barclays
- Twist Bioscience price target raised to $32 from $26 at Evercore ISI
- Twist Bioscience sees FY24 revenue $285M-$290M, consensus $298.67M
